About
About Neos Therapeutics, Inc
Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas. As of March 19, 2021, Neos Therapeutics, Inc. operates as a subsidiary of Aytu BioScience, Inc.
Visit company website
5 years, 4 months ago
Neos Therapeutics, Inc is currently in a long term uptrend where the price is trading 49.9% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
Neos Therapeutics, Inc's total revenue sank by 28.5% to $13M since the same quarter in the previous year.
Its net income has dropped by 139.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 53.0% to $-2M since the same quarter in the previous year.
Based on the above factors, Neos Therapeutics, Inc gets an overall score of 3/5.